Document Type : Original Article
Author
College of Medicine, Ashur University, Baghdad, Iraq
Abstract
BACKGROUND: Breast cancer is the most common malignancy in women, with 15–20% being HER2-positive, an aggressive subtype treated with Trastuzumab. Despite its survival benefits, Trastuzumab may cause cardiotoxicity, typically monitored by left ventricular ejection fraction (LVEF). This study assessed Trastuzumab’s impact on LVEF and related factors among women with breast cancer in Baghdad.
METHODS: This retrospective observational cohort study included 60 women with stage I–III HER2-positive breast cancer treated at Al-Amal National Oncology Hospital between January 2023 and May 2024. Baseline demographic, clinical, and echocardiographic parameters were collected, with follow-up assessments every three weeks during therapy and after the final cycle. Data were analyzed using SPSS version 27.
RESULTS: A P-value <0.05 was considered statistically significant. Mean LVEF declined significantly from 64.98% ± 5.50 to 62.02% ± 6.91 post-treatment (P < 0.001). The proportion of patients with impaired left ventricular diastolic function increased from 11.7% to 26.7% (P = 0.003). An LVEF decline of ≥10% was considered clinically meaningful. Traditional risk factors were not associated with LVEF decline, whereas baseline LVDF (OR 10.80; 95% CI: 2.21–17.42; P = 0.007) and post-treatment LVDF (OR 8.20; 95% CI: 1.74–13.58; P = 0.008) were significantly linked to LVEF decline.
CONCLUSION: Trastuzumab can cause early cardiac function decline, which is not always detected by LVEF alone. Assessment of left ventricular diastolic function at baseline and during therapy can identify high-risk patients, enabling timely monitoring and management to balance anticancer benefits with cardiotoxic risk.
Keywords
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-49. https://doi.org/10.3322/caac.21660
2. O’Sullivan CC, Loprinzi CL, Haddad TC, editors. Updates in the evaluation and management of breast cancer. Mayo Clinic Proceedings; 2018: Elsevier.
3. Shaath H, Elango R, Alajez NM. Molecular Classification of Breast Cancer Utilizing Long Non-Coding RNA (lncRNA) Transcriptomes Identifies Novel Diagnostic lncRNA Panel for Triple-Negative Breast Cancer. Cancers (Basel). 2021 Oct 26;13(21):5350. https://doi.org/10.3390/cancers13215350
4. Exman P, Tolaney SM. HER2-positive metastatic breast cancer: a comprehensive review. Clin Adv Hematol Oncol. 2021 Jan;19(1):40-50.
5. Zhang L, Yu J. Role of apoptosis in colon cancer biology, therapy, and prevention. Curr Colorectal Cancer Rep. 2013 Dec;9(4):10.1007/s11888-013-0188-z. https://doi.org/10.1007/s11888-013-0188-z
6. Gonzalez-Angulo AM, Litton JK, Broglio KR, Meric-Bernstam F, Rakkhit R, Cardoso F, et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol. 2009 Dec 1;27(34):5700-6. https://doi.org/10.1200/jco.2009.23.2025
7. Tinoco G, Warsch S, Glück S, Avancha K, Montero AJ. Treating breast cancer in the 21st century: emerging biological therapies. J Cancer. 2013;4(2):117-32. https://doi.org/10.7150/jca.4925
8. Pinto AC, Ades F, de Azambuja E, Piccart-Gebhart M. Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapies. Breast. 2013 Aug;22 Suppl 2:S152-5. https://doi.org/10.1016/j.breast.2013.07.029
9. Spector NL, Blackwell KL. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2009 Dec 1;27(34):5838-47. https://doi.org/10.1200/jco.2009.22.1507
10. Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res. 2001 Jun 15;61(12):4744-9.
11. Tsao LC, Crosby EJ, Trotter TN, Agarwal P, Hwang BJ, Acharya C, et al. CD47 blockade augmentation of trastuzumab antitumor efficacy dependent on antibody-dependent cellular phagocytosis. JCI Insight. 2019 Dec 19;4(24):e131882. https://doi.org/10.1172/jci.insight.131882
12. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016 Sep 21;37(36):2768-801. https://doi.org/10.1093/eurheartj/ehw211
13. Tan-Chiu E, Yothers G, Romond E, Geyer Jr CE, Ewer M, Keefe D, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol. 2005 Nov 1;23(31):7811-9. https://doi.org/10.1200/jco.2005.02.4091
14. Viani GA, Afonso SL, Stefano EJ, De Fendi LI, Soares FV. Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer. 2007 Aug 8;7:153. https://doi.org/10.1186/1471-2407-7-153
15. Janbabai G, Nabati M, Faghihinia M, Azizi S, Borhani S, Yazdani J. Effect of Enalapril on Preventing Anthracycline-Induced Cardiomyopathy. Cardiovasc Toxicol. 2017 Apr;17(2):130-9. https://doi.org/10.1007/s12012-016-9365-z
16. U.S. Food and Drug Administration. Herceptin (trastuzumab) prescribing information. Silver Spring.
17. Sherief LM, Kamal AG, Khalek EA, Kamal NM, Soliman AA, Esh AM. Biomarkers and early detection of late onset anthracycline-induced cardiotoxicity in children. Hematology. 2012 May;17(3):151-6. https://doi.org/10.1179/102453312x13376952196412
18. Zaya M, Mehta P, Mohammadi AH, Agarwal M, Sedlak T, Johnson BD, et al. Microvascular coronary dysfunction, left ventricular volumes and mass: results from the Women’s Ischemia Syndrome Evaluation–Coronary Vascular Dysfunction study. J Am Coll Cardiol. 2013;61(10 Suppl):E1442.
19. Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA. 2003 Jan 8;289(2):194-202. https://doi.org/10.1001/jama.289.2.194
20. Lee BH, Goodenday LS, Muswick GJ, Yasnoff WA, Leighton RF, Skeel RT. Alterations in left ventricular diastolic function with doxorubicin therapy. J Am Coll Cardiol. 1987 Jan;9(1):184-8. https://doi.org/10.1016/s0735-1097(87)80099-2
21. Marchandise B, Schroeder E, Bosly A, Doyen C, Weynants P, Kremer R, et al. Early detection of doxorubicin cardiotoxicity: interest of Doppler echocardiographic analysis of left ventricular filling dynamics. Am Heart J. 1989 Jul;118(1):92-8. https://doi.org/10.1016/0002-8703(89)90077-x
22. Bergamini C, Torelli F, Ghiselli L, Rossi A, Trevisani L, Vinco G, et al. Left ventricular end-diastolic volume as early indicator of trastuzumab-related cardiotoxicity in HER2+ breast cancer patients: results from a single-center retrospective study. Minerva Cardioangiol. 2017 Jun;65(3):278-87. https://doi.org/10.23736/s0026-4725.16.04278-x
23. Fallah-Rad N, Walker JR, Wassef A, Lytwyn M, Bohonis S, Fang T, et al. The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy. J Am Coll Cardiol. 2011 May 31;57(22):2263-70. https://doi.org/10.1016/j.jacc.2010.11.063
24. Dores H, Abecasis J, Correia MJ, Gândara F, Fonseca C, Azevedo J, et al. Detection of early sub-clinical trastuzumab-induced cardiotoxicity in breast cancer patients. Arq Bras Cardiol. 2013 Apr;100(4):328-32.
25. Youlden DR, Cramb SM, Yip CH, Baade PD. Incidence and mortality of female breast cancer in the Asia-Pacific region. Cancer Biol Med. 2014 Jun;11(2):101-15. https://doi.org/10.7497/j.issn.2095-3941.2014.02.005
26. Leong SP, Shen Z-Z, Liu T-J, Agarwal G, Tajima T, Paik N-S, et al. Is breast cancer the same disease in Asian and Western countries? World J Surg. 2010 Oct;34(10):2308-24. https://doi.org/10.1007/s00268-010-0683-1
27. Wong FY, Tham WY, Nei WL, Lim C, Miao H. Age exerts a continuous effect in the outcomes of Asian breast cancer patients treated with breast-conserving therapy. Cancer Commun (Lond). 2018 Jun 26;38(1):39. https://doi.org/10.1186/s40880-018-0310-3
28. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005 Oct 20;353(16):1659-72. https://doi.org/10.1056/nejmoa052306
29. Nagueh SF, Smiseth OA, Appleton CP, Byrd BF, Dokainish H, Edvardsen T, et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2016 Dec;17(12):1321-60. https://doi.org/10.1093/ehjci/jew082
30. Park H, Kim KH, Kim HY, Cho JY, Yoon HJ, Hong YJ, et al. Left atrial longitudinal strain as a predictor of Cancer therapeutics-related cardiac dysfunction in patients with breast Cancer. Cardiovasc Ultrasound. 2020 Jul 21;18(1):28. https://doi.org/10.1186/s12947-020-00210-5
31. Upshaw JN, Finkelman B, Hubbard RA, Smith AM, Narayan HK, Arndt L, et al. Comprehensive Assessment of Changes in Left Ventricular Diastolic Function With Contemporary Breast Cancer Therapy. JACC Cardiovasc Imaging. 2020 Jan;13(1 Pt 2):198-210. https://doi.org/10.1016/j.jcmg.2019.07.018
32. Cochet A, Quilichini G, Dygai-Cochet I, Touzery C, Toubeau M, Berriolo-Riedinger A, et al. Baseline diastolic dysfunction as a predictive factor of trastuzumab-mediated cardiotoxicity after adjuvant anthracycline therapy in breast cancer. Breast Cancer Res Treat. 2011 Dec;130(3):845-54. https://doi.org/10.1007/s10549-011-1714-9
33. Al-Ali BA, Hatef ZS, Mohammed HR. Cardiotoxicity associated with trastuzumab and anthracyclines in treating breast cancer patients. Lat Am J Pharm. 2021;40(Suppl Issue):135-40.
34. Al-Saleh K, Abdel-Warith A, Alghamdi M, Aldiab A, Ali A, Alsaeed EF, et al. Incidence of trastuzumab-induced cardiotoxicity and impact of body mass index in patients with breast cancer: Results from a Saudi tertiary cancer center. Mol Clin Oncol. 2022 Apr;16(4):78. https://doi.org/10.3892/mco.2022.2511
35. Farolfi A, Melegari E, Aquilina M, Scarpi E, Ibrahim T, Maltoni R, et al. Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factors. Heart. 2013 May;99(9):634-9. https://doi.org/10.1136/heartjnl-2012-303151
36. Abdel-Razaq W, Alzahrani M, Al Yami M, Almugibl F, Almotham M, Alregaibah R. Risk Factors Associated with Trastuzumab-induced Cardiotoxicity in Patients with Human Epidermal Growth Factor Receptor 2-positive Breast Cancer. J Pharm Bioallied Sci. 2019 Oct-Dec;11(4):348-54. https://doi.org/10.4103/jpbs.jpbs_276_18
37. Chen J, Long JB, Hurria A, Owusu C, Steingart RM, Gross CP. Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Coll Cardiol. 2012 Dec 18;60(24):2504-12. https://doi.org/10.1016/j.jacc.2012.07.068
)